Enanta Pharmaceuticals (ENTA) EBITDA (2012 - 2026)
Enanta Pharmaceuticals posted quarterly EBITDA of -$11.9 million for Q1 2026, up 51.68% year-on-year from -$7.8 million in Q1 2025, and down 5.32% on a QoQ basis from -$11.3 million in Q4 2025.
Enanta Pharmaceuticals (ENTA) has 15 years of EBITDA data on file, last reported at -$11.9 million in Q1 2026.
- For the quarter ending Q1 2026, EBITDA rose 51.68% year-over-year to -$11.9 million; the trailing twelve-month figure through Mar 2026 stood at -$60.4 million (up 40.86% YoY), and the FY2025 full-year result was -$85.3 million, up 29.86% from the prior year.
- EBITDA for Q1 2026 stood at -$11.9 million, down from -$11.3 million in the prior quarter.
- Across five years, EBITDA topped out at -$11.3 million in Q4 2025 and bottomed at -$39.5 million in Q1 2023.
- The 5-year median for EBITDA is -$29.9 million (2024), against an average of -$27.1 million.
- The widest annual swing landed in 2023, when EBITDA fell 16.56%; it then surged 52.2% in 2025.
- A 5-year view of EBITDA shows it stood at -$30.0 million in 2022, then decreased by 16.24% to -$34.9 million in 2023, then jumped by 32.51% to -$23.5 million in 2024, then soared by 52.2% to -$11.3 million in 2025, then decreased by 5.32% to -$11.9 million in 2026.
- The last three EBITDA figures came in at -$11.9 million (Q1 2026), -$11.3 million (Q4 2025), and -$18.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 201.19 Mn |
| 10 | Enanta Pharmaceuticals | 367.22 Mn | 203.44 Mn | - | -11.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11.85 Mn |
| Dec 31, 2025 | -11.25 Mn |
| Sep 30, 2025 | -18.39 Mn |
| Jun 30, 2025 | -18.89 Mn |
| Mar 31, 2025 | -24.53 Mn |
| Dec 31, 2024 | -23.54 Mn |
| Sep 30, 2024 | -29.85 Mn |
| Jun 30, 2024 | -24.19 Mn |
| Mar 31, 2024 | -32.77 Mn |
| Dec 31, 2023 | -34.89 Mn |
| Sep 30, 2023 | -31.03 Mn |
| Jun 30, 2023 | -36.71 Mn |
| Mar 31, 2023 | -39.45 Mn |
| Dec 31, 2022 | -30.01 Mn |
| Sep 30, 2022 | -27.05 Mn |
| Jun 30, 2022 | -32.54 Mn |
| Mar 31, 2022 | -33.85 Mn |
| Dec 31, 2021 | -30.41 Mn |
| Sep 30, 2021 | -33.73 Mn |
| Jun 30, 2021 | -33.85 Mn |
| Mar 31, 2021 | -29.70 Mn |
| Dec 31, 2020 | -12.30 Mn |
| Sep 30, 2020 | -19.78 Mn |
| Jun 30, 2020 | -22.85 Mn |
| Mar 31, 2020 | -11.88 Mn |
| Dec 31, 2019 | 12.87 Mn |
| Sep 30, 2019 | 6.43 Mn |
| Jun 30, 2019 | 3.76 Mn |
| Mar 31, 2019 | -1.30 Mn |
| Dec 31, 2018 | 27.86 Mn |
| Sep 30, 2018 | 34.45 Mn |
| Jun 30, 2018 | 22.64 Mn |
| Mar 31, 2018 | 16.86 Mn |
| Dec 31, 2017 | 14.38 Mn |
| Sep 30, 2017 | 54.30 Mn |
| Jun 30, 2017 | -13.13 Mn |
| Mar 31, 2017 | -9.51 Mn |
| Dec 31, 2016 | -7.05 Mn |
| Sep 30, 2016 | -3.10 Mn |
| Jun 30, 2016 | -1.09 Mn |
| Mar 31, 2016 | -565,000.00 |
| Dec 31, 2015 | 35.59 Mn |
| Sep 30, 2015 | 3.67 Mn |
| Jun 30, 2015 | 1.70 Mn |
| Mar 31, 2015 | 48.56 Mn |
| Dec 31, 2014 | 70.21 Mn |
| Sep 30, 2014 | -5.33 Mn |
| Jun 30, 2014 | 34.90 Mn |
| Mar 31, 2014 | -5.13 Mn |
| Dec 31, 2013 | -5.46 Mn |
| Sep 30, 2013 | -4.70 Mn |
| Jun 30, 2013 | -4.18 Mn |
| Mar 31, 2013 | -4.00 Mn |
| Dec 31, 2012 | 21.91 Mn |
| Sep 30, 2012 | -4.10 Mn |
| Jun 30, 2012 | -3.53 Mn |
| Mar 31, 2012 | 32.10 Mn |